|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC24A3 |
Gene summary for SLC24A3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC24A3 | Gene ID | 57419 |
| Gene name | solute carrier family 24 member 3 | |
| Gene Alias | NCKX3 | |
| Cytomap | 20p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q9HC58 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57419 | SLC24A3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.37e-03 | -1.98e-01 | 0.0155 |
| 57419 | SLC24A3 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.99e-03 | 2.95e-01 | 0.0216 |
| 57419 | SLC24A3 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.43e-06 | 5.93e-01 | -0.1464 |
| 57419 | SLC24A3 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.72e-07 | 3.34e-01 | 0.096 |
| 57419 | SLC24A3 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.42e-04 | 5.62e-01 | 0.0131 |
| 57419 | SLC24A3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.17e-05 | -2.63e-01 | 0.294 |
| 57419 | SLC24A3 | A002-C-021 | Human | Colorectum | FAP | 1.47e-02 | 4.15e-01 | 0.1171 |
| 57419 | SLC24A3 | A015-C-005 | Human | Colorectum | FAP | 7.66e-09 | 6.71e-01 | -0.0336 |
| 57419 | SLC24A3 | F034 | Human | Colorectum | FAP | 1.48e-02 | 5.02e-01 | -0.0665 |
| 57419 | SLC24A3 | CRC-3-11773 | Human | Colorectum | CRC | 1.09e-03 | -2.43e-01 | 0.2564 |
| 57419 | SLC24A3 | C09 | Human | Oral cavity | OSCC | 1.23e-04 | 1.85e-01 | 0.1431 |
| 57419 | SLC24A3 | EOLP-1 | Human | Oral cavity | EOLP | 6.05e-32 | 1.04e+00 | -0.0202 |
| 57419 | SLC24A3 | EOLP-2 | Human | Oral cavity | EOLP | 2.70e-30 | 1.04e+00 | -0.0203 |
| 57419 | SLC24A3 | NEOLP-1 | Human | Oral cavity | NEOLP | 5.26e-27 | 7.96e-01 | -0.0194 |
| 57419 | SLC24A3 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.42e-12 | 4.16e-01 | -0.0196 |
| 57419 | SLC24A3 | NEOLP-3 | Human | Oral cavity | NEOLP | 1.30e-03 | 2.73e-01 | -0.0191 |
| 57419 | SLC24A3 | SYSMH3 | Human | Oral cavity | OSCC | 1.14e-03 | 3.16e-02 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0001503 | Colorectum | AD | ossification | 106/3918 | 408/18723 | 7.68e-03 | 4.64e-02 | 106 |
| GO:00015031 | Colorectum | SER | ossification | 82/2897 | 408/18723 | 6.76e-03 | 4.78e-02 | 82 |
| GO:0150104 | Colorectum | MSS | transport across blood-brain barrier | 28/3467 | 87/18723 | 1.54e-03 | 1.41e-02 | 28 |
| GO:0010232 | Colorectum | MSS | vascular transport | 28/3467 | 88/18723 | 1.87e-03 | 1.64e-02 | 28 |
| GO:00015032 | Colorectum | MSS | ossification | 96/3467 | 408/18723 | 6.09e-03 | 4.07e-02 | 96 |
| GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
| GO:01501041 | Colorectum | FAP | transport across blood-brain barrier | 25/2622 | 87/18723 | 2.63e-04 | 3.59e-03 | 25 |
| GO:00102321 | Colorectum | FAP | vascular transport | 25/2622 | 88/18723 | 3.19e-04 | 4.12e-03 | 25 |
| GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
| GO:0003018 | Colorectum | FAP | vascular process in circulatory system | 56/2622 | 263/18723 | 7.67e-04 | 8.12e-03 | 56 |
| GO:00015033 | Colorectum | FAP | ossification | 79/2622 | 408/18723 | 1.53e-03 | 1.37e-02 | 79 |
| GO:00357251 | Colorectum | CRC | sodium ion transmembrane transport | 39/2078 | 178/18723 | 2.30e-05 | 6.60e-04 | 39 |
| GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
| GO:00030181 | Colorectum | CRC | vascular process in circulatory system | 45/2078 | 263/18723 | 2.10e-03 | 2.08e-02 | 45 |
| GO:00015034 | Colorectum | CRC | ossification | 64/2078 | 408/18723 | 2.73e-03 | 2.49e-02 | 64 |
| GO:01501042 | Colorectum | CRC | transport across blood-brain barrier | 18/2078 | 87/18723 | 6.50e-03 | 4.69e-02 | 18 |
| GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
| GO:000150322 | Oral cavity | EOLP | ossification | 70/2218 | 408/18723 | 8.89e-04 | 6.81e-03 | 70 |
| GO:00725032 | Oral cavity | EOLP | cellular divalent inorganic cation homeostasis | 75/2218 | 486/18723 | 9.77e-03 | 4.42e-02 | 75 |
| GO:000150331 | Oral cavity | NEOLP | ossification | 81/2005 | 408/18723 | 2.67e-08 | 1.15e-06 | 81 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC24A3 | SNV | Missense_Mutation | c.363N>G | p.Phe121Leu | p.F121L | Q9HC58 | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| SLC24A3 | SNV | Missense_Mutation | novel | c.578N>T | p.Cys193Phe | p.C193F | Q9HC58 | protein_coding | tolerated(0.32) | benign(0.115) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC24A3 | SNV | Missense_Mutation | c.1573N>A | p.Asp525Asn | p.D525N | Q9HC58 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SLC24A3 | SNV | Missense_Mutation | c.1144G>A | p.Glu382Lys | p.E382K | Q9HC58 | protein_coding | tolerated(0.07) | benign(0.186) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| SLC24A3 | SNV | Missense_Mutation | novel | c.979N>C | p.Glu327Gln | p.E327Q | Q9HC58 | protein_coding | deleterious(0.02) | possibly_damaging(0.889) | TCGA-OL-A5D7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| SLC24A3 | insertion | In_Frame_Ins | novel | c.646_647insCTATCTCCAAATGCCAAGAACATTTTCCCCTGGATC | p.Asp216delinsAlaIleSerLysCysGlnGluHisPheProLeuAspHis | p.D216delinsAISKCQEHFPLDH | Q9HC58 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| SLC24A3 | insertion | Nonsense_Mutation | novel | c.579_580insCTGTAGATTCTGAGAACAATCTA | p.Ile194LeufsTer2 | p.I194Lfs*2 | Q9HC58 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC24A3 | SNV | Missense_Mutation | rs150240114 | c.914N>A | p.Arg305His | p.R305H | Q9HC58 | protein_coding | tolerated(0.12) | benign(0.045) | TCGA-AA-3675-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SLC24A3 | SNV | Missense_Mutation | rs144636987 | c.326N>T | p.Ala109Val | p.A109V | Q9HC58 | protein_coding | deleterious(0) | benign(0.035) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SLC24A3 | SNV | Missense_Mutation | rs144636987 | c.326N>T | p.Ala109Val | p.A109V | Q9HC58 | protein_coding | deleterious(0) | benign(0.035) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |